Use of fenofibrate on cardiovascular outcomes in statin users with metabolic syndrome: propensity matched cohort study.

ABSTRACT:

Objective

To investigate whether fenofibrate as add-on to statin treatment reduce persistent cardiovascular risk in adults with metabolic syndrome in a real world setting.

Design

Propensity matched cohort study.

Setting

Population based cohort in Korea.

Participants

29 771 adults with metabolic syndrome (≥40 years) receiving statin treatment. 2156 participants receiving combined treatment (statin plus fenofibrate) were weighted based on propensity score in a 1:5 ratio with 8549 participants using statin only treatment.

Main outcome measure

Primary outcome was composite cardiovascular events including incident coronary heart disease, ischaemic stroke, and death from cardiovascular causes.

Results

The incidence rate per 1000 person years of composit

SUBMITTER: Kim NH 

PROVIDER: S-EPMC6763755 | biostudies-literature | 2019 Sep

REPOSITORIES: biostudies-literature